Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer

• Jianfa Li,
• Chengle Zhuang,
• Yuchen Liu,
• Mingwei Chen,
• Yincong Chen,
• Zhicong Chen,
• Anbang He,
• Junhao Lin,
• Yonghao Zhan,
• Li Liu,
• Wen Xu,
• Guoping Zhao,
• Yinglu Guo,
• Hanwei Wu,
• Zhiming Cai,
• Weiren Huang

Affiliations

Jianfa Li

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Chengle Zhuang

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Yuchen Liu

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Mingwei Chen

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Yincong Chen

Guangdong Province, Shantou University Medical College

Zhicong Chen

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Anbang He

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Junhao Lin

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Yonghao Zhan

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Li Liu

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Wen Xu

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Guoping Zhao

Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai

Yinglu Guo

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center

Hanwei Wu

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Zhiming Cai

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University

Weiren Huang

Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University